Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab

NCT01748292 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Macular Degeneration

Interventions

DRUG: 0.5 mg ranibizumab

Sponsor

Charles C Wykoff, PhD, MD

Collaborators

[object Object]